Clinical Trials Logo

Pre-eclampsia clinical trials

View clinical trials related to Pre-eclampsia.

Filter by:

NCT ID: NCT06417411 Recruiting - Sickle Cell Disease Clinical Trials

LEARNER- Low dosE AspiRiN prEterm tRial (Angola)

LEARNER
Start date: March 16, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being conducted to evaluate the safety and effect of starting daily use of low dose (100 mg) aspirin in pregnant women with sickle cell disease, who are being followed in two county hospitals in Angola, in the first trimester versus the second trimester of the gestational period.

NCT ID: NCT06416995 Recruiting - Preterm Birth Clinical Trials

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

Start date: March 3, 2023
Phase:
Study type: Observational

Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.

NCT ID: NCT06414655 Recruiting - Pre-Eclampsia Clinical Trials

Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China

ChiTwiMC
Start date: March 1, 2024
Phase:
Study type: Observational

Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China (ChiTwiMC) is supported by National Key Research and Development Program of China - Reproductive Health and Women's and Children's Health Protection Project. This project is funded by the Ministry of Science and Technology of China under grant number 2023YFC2705900. The ChiTwiMC cohort is led by Professor Wei Yuan from the Department of Gynecology and Obstetrics at Peking University Third Hospital.

NCT ID: NCT06413576 Recruiting - Critical Illness Clinical Trials

Homocysteine in Critically Ill Preeclampsia

Start date: January 19, 2024
Phase:
Study type: Observational

Preeclampsia is a disorder characterized by the new onset of hypertension and proteinuria typically presenting after 20 weeks of gestation. Elevated circulating homocysteine is a risk factor for endothelial dysfunction and vascular diseases such as atherosclerosis and occlusive disorders. Our study is to investigate the association between elevated blood homocysteine levels and complications in pregnant women in order to conclude the clinical utility of homocysteine as a marker of severity in the cases of pre-eclampsia.

NCT ID: NCT06408181 Not yet recruiting - Pre-Eclampsia Clinical Trials

APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia

APPLE
Start date: May 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are: Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.

NCT ID: NCT06402604 Enrolling by invitation - Clinical trials for Stress, Psychological

Stress Reduction in Formerly Preeclamptic Women; Sofa or Sports

SOS
Start date: March 21, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate stress and cardiovascular risk factors in women with preeclampsia in the medical history. The main questions it aims to answer are: - to improve our understanding of the underlying psychological and physical stress factors in relation to the circulatory risk profile in women with a history of preeclampsia - to examine the effects of mindfullness based stress reduction (MBSR) or aerobic exercise training on hair cortisol and symptoms of mental stress. Participants will undergo pre- and post-intervention pre-conceptional standard cardiovascular assessments, head tilt test and give a hair sample. As intervention they will sport or do mindfulness for 3 months.They will be compared with a control group.

NCT ID: NCT06395974 Recruiting - Preeclampsia Clinical Trials

Fetal Renal Artery Doppler in Patients With Preeclampsia

Start date: November 1, 2023
Phase:
Study type: Observational

Preeclampsia is a major devastating disorder affects 2:10% of pregnancies worldwide. preeclampsia may be associated with placental insufficiency which may cause fetal blood redistribution to essential organs like brain, heart, kidney.

NCT ID: NCT06387784 Not yet recruiting - Pre-Eclampsia Clinical Trials

Acute Beetroot Juice Supplementation in Pre-eclampsia Pregnancies

BEET_PE
Start date: June 2024
Phase: N/A
Study type: Interventional

Pre-eclampsia is a serious condition that typically affects pregnant women after the 20th week of pregnancy, characterized by high blood pressure and damage to organs such as the kidneys and liver. Currently, treatment options are limited, which has prompted researchers to explore alternative approaches. One such promising alternative is dietary nitrate found in vegetables like beetroot, as nitrate can be converted into nitric oxide in the body, which helps lower blood pressure. This study aims to determine the acute effects of nitrate-rich beetroot juice on blood pressure, several blood and salivary markers in pregnant women with pre-eclampsia. Furthermore, the study will assess fetal blood flow using Doppler ultrasound. The investigators want to understand the kinetics of nitrate and nitric oxide metabolites and assess the temporal dependency of the hypotensive response. Through this investigation, the investigators seek evidence of nitrate-enriched beetroot juice as an adjunct therapy in managing pre-eclampsia.

NCT ID: NCT06385600 Not yet recruiting - Clinical trials for Severe Pre-eclampsia

Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

The only effective treatment of severe preeclampsia is delivery of the fetus but immediate antihypertensive treatment is given to stabilize the patient and prevent further complications. All antihypertensive medication can potentially cross the placenta. At this time, there are no randomized control trials to base a recommendation for the use of one antihypertensive agent over another. However, certain medications are effective in lowering blood pressure with an acceptable safety profile in pregnancy. The choice of therapy depends on the acuity and severity of hypertension

NCT ID: NCT06385366 Not yet recruiting - Preterm Birth Clinical Trials

Developing & Evaluating Models for Early Predicting Obstetrical Diseases in Pregnant Women by Non-invasive Prenatal Test

Start date: May 15, 2024
Phase:
Study type: Observational

This is Observational study, aiming to investigate the potentiality of cffDNA and cfRNA by a non-invasive test, in combination with clinical characteristics, to establish models for early screening and predicting high-risk pregnancy of PE, SPB, and GDM in Vietnam.